It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases ...

Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a ...

Last year, Boehringer Ingelheim’s Pradaxa picked up an edge on its new-age anticoagulant rivals when the FDA approved a reversal agent. Now, the agency has turned back an antidote to blockbuster ...

Boehringer Ingelheim already had the FDA's "breakthrough" designation on idarucizumab, an antidote to its blockbuster anticoagulant Pradaxa. Now, the reversal agent has stepped on the agency's fast ...

MONDAY, Oct. 3, 2016 -- The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in patients with the abnormal heartbeat known as atrial fibrillation, new research ...

Millions of Americans take blood thinners to prevent the formation of blood clots and stroke, including many people who have been diagnosed with atrial fibrillation, a heart rhythm disorder. Yet ...

The quality and depth of clinical trials of the blood-thinner Xarelto could be a key issue when the first trials over the drug begin in Philadelphia courtrooms. With the first trial of more than 800 ...

Johnson & Johnson and Bayer said Monday that they had agreed to pay $775 million to settle about 25,000 lawsuits involving the blood thinner Xarelto, which they jointly sell. The settlement, which ...

Drug regulators said an experimental stroke preventer from Bayer and Johnson & Johnson is not ready for approval and raised questions about its effectiveness, sending Bayer shares down more than 7 ...

NEW YORK (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose hardships and risks have deterred ...